# Comparison of Safety and Efficacy of de Novo Everolimus

> **NCT04906304** · NA · COMPLETED · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 35 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** Everolimus Pill
- **DRUG:** Sandimmun (Neoral) dose plus cellcept

## Key facts

- **NCT ID:** NCT04906304
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-01
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906304, "Comparison of Safety and Efficacy of de Novo Everolimus". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04906304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*